Chemical Compound Review:
KB-52511 [(3-aminopyridin-2- yl)methylideneamino]thi...
Synonyms:
143621-35-6
Feun,
Modiano,
Lee,
Mao,
Marini,
Savaraj,
Plezia,
Almassian,
Colacino,
Fischer,
MacDonald,
Giles,
Fracasso,
Kantarjian,
Cortes,
Brown,
Verstovsek,
Alvarado,
Thomas,
Faderl,
Garcia-Manero,
Wright,
Samson,
Cahill,
Lambert,
Plunkett,
Sznol,
DiPersio,
Gandhi,
Chen,
Yao,
Lu,
Jiang,
Whipple,
Liao,
Ghanbari,
Almassian,
Tortella,
Dave,
Richardson,
- Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. Liu, M.C., Lin, T.S., Sartorelli, A.C. J. Med. Chem. (1992)
- PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating Bcl-2 expression. Chen, R.W., Yao, C., Lu, X.C., Jiang, Z.G., Whipple, R., Liao, Z., Ghanbari, H.A., Almassian, B., Tortella, F.C., Dave, J.R. Neuroscience (2005)
- Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Foltz, L.M., Dalal, B.I., Wadsworth, L.D., Broady, R., Chi, K., Eisenhauer, E., Kobayashi, K., Kollmannsburger, C. Am. J. Hematol. (2006)
- Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Giles, F.J., Fracasso, P.M., Kantarjian, H.M., Cortes, J.E., Brown, R.A., Verstovsek, S., Alvarado, Y., Thomas, D.A., Faderl, S., Garcia-Manero, G., Wright, L.P., Samson, T., Cahill, A., Lambert, P., Plunkett, W., Sznol, M., DiPersio, J.F., Gandhi, V. Leuk. Res. (2003)
- Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Yee, K.W., Cortes, J., Ferrajoli, A., Garcia-Manero, G., Verstovsek, S., Wierda, W., Thomas, D., Faderl, S., King, I., O'brien, S.M., Jeha, S., Andreeff, M., Cahill, A., Sznol, M., Giles, F.J. Leuk. Res. (2006)
- In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Shao, J., Zhou, B., Zhu, L., Qiu, W., Yuan, Y.C., Xi, B., Yen, Y. Cancer Res. (2004)
- In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone). Barker, C.A., Burgan, W.E., Carter, D.J., Cerna, D., Gius, D., Hollingshead, M.G., Camphausen, K., Tofilon, P.J. Clin. Cancer Res. (2006)
- Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren, J., Modiano, M., Clairmont, C., Lambert, P., Savaraj, N., Doyle, T., Sznol, M. Clin. Cancer Res. (2003)
- Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Feun, L., Modiano, M., Lee, K., Mao, J., Marini, A., Savaraj, N., Plezia, P., Almassian, B., Colacino, E., Fischer, J., MacDonald, S. Cancer Chemother. Pharmacol. (2002)
- Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. Alvero, A.B., Chen, W., Sartorelli, A.C., Schwartz, P., Rutherford, T., Mor, G. J. Soc. Gynecol. Investig. (2006)
- A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Yen, Y., Margolin, K., Doroshow, J., Fishman, M., Johnson, B., Clairmont, C., Sullivan, D., Sznol, M. Cancer Chemother. Pharmacol. (2004)
- Iron chelators as therapeutic agents for the treatment of cancer. Richardson, D.R. Crit. Rev. Oncol. Hematol. (2002)
- Therapeutic potential of iron chelators in cancer therapy. Richardson, D.R. Adv. Exp. Med. Biol. (2002)
- A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Shao, J., Zhou, B., Di Bilio, A.J., Zhu, L., Wang, T., Qi, C., Shih, J., Yen, Y. Mol. Cancer Ther. (2006)
- Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Chaston, T.B., Lovejoy, D.B., Watts, R.N., Richardson, D.R. Clin. Cancer Res. (2003)